Compare ANDE & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | URGN |
|---|---|---|
| Founded | 1947 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2005 | 2016 |
| Metric | ANDE | URGN |
|---|---|---|
| Price | $65.54 | $47.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $75.00 | $29.29 |
| AVG Volume (30 Days) | 294.2K | ★ 808.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $11,008,928,000.00 | $1,128,000.00 |
| Revenue This Year | $7.28 | $129.09 |
| Revenue Next Year | $3.57 | $70.96 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.63 | $15.86 |
| 52 Week High | $82.11 | $48.03 |
| Indicator | ANDE | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.51 | 67.02 |
| Support Level | $64.75 | $18.23 |
| Resistance Level | $73.40 | N/A |
| Average True Range (ATR) | 3.32 | 2.41 |
| MACD | -0.87 | 0.07 |
| Stochastic Oscillator | 1.53 | 78.59 |
Andersons Inc is an agriculture and renewable fuels company. Its operations are classified into two reportable business segments: Agribusiness, which generates maximum revenue, and Renewables. The Agribusiness segment includes merchandising and managing logistics across various commodities, as well as being a manufacturer, distributor, and retailer of agricultural and related plant nutrients. The segment specializes in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. The Renewables segment mainly produces, purchases, and sells ethanol and co-products. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.